# US 2019/0375730 A1 · Maleate salts of a quinazoline derivative useful as an antiangiogenic agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375730 A1
- Document ID: US20190375730A1
- Status: Published application
- Kind: A1
- Application number: 16/240,587
- Filed: 2019-01-04
- Published: 2019-12-12
- Earliest claimed: 2003-12-24
- Assignees: AstraZeneca AB
- Applicants: AstraZeneca AB
- Inventors: James MCCABE
- Web page: https://patentgrep.com/patent/US20190375730A1

## CPC

- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 57/145: Maleic acid
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compositions containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for inhibiting VEGF receptor tyrosine kinase in a warm-blooded animal in need of such treatment which comprises
orally administering to said animal an effective amount of a pharmaceutical composition comprising crystalline Form A of 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline maleate, wherein said warm-blooded animal in need of such treatment has a solid tumor cancer that is recurrent, and
optionally administering at least one additional treatment chosen from surgery, radiotherapy, and chemotherapy.

### Claim 22 (depends on 21)

The method according to claim 21, herein said cancer is a female reproductive cancer.

### Claim 23 (depends on 21)

The method according to claim 21, wherein the daily dose of Form A of 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline maleate administered to said animal ranges from 0.03 mg/kg to 0.5 mg/kg.

### Claim 24 (depends on 21)

The method according to claim 21, wherein said chemotherapy comprises at least one therapeutic agent chosen from (i) other antiangiogenic agents; (ii) cytostatic agents; and (iii) antiproliferative/antineoplastic drugs.

### Claim 25 (depends on 24)

The method according to claim 24, herein said antiproliferative/antineoplastic drugs are chosen from platinum derivatives.
